Omeros (OMER)

• Market cap: $795M
• 1 day: -1.52%
• 5 days: -7.26%
• 1 month: -24.59%
• 3 months: -8.35%
• 6 months: 13.43%
• Year to date: -32.97%
• 1 year: 230.72%
• 5 years: -28.47%
• 10 years: -6.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Employees: 175